Cited by 25CRISPR and Genetic EngineeringRNA Interference and Gene DeliveryVirus-based gene therapy research

Nanoblades allow high-level genome editing in murine and human organoids

Open access
Tiroille, Victor, Krug, Adrien, Bokobza, Emma, Kahi, Michel, Bulcaen, Mattijs, Ensinck, Marjolein M., Geurts, Maarten H., Hendriks, Delilah +14 more·2023·Molecular Therapy - Nucleic Acids

Abstract

Genome engineering has become more accessible thanks to the CRISPR-Cas9 gene-editing system. However, using this technology in synthetic organs called "organoids" is still very inefficient. This is due to the delivery methods for the CRISPR-Cas9 machinery, which include electroporation of CRISPR-Cas9 DNA, mRNA, or ribonucleoproteins containing the Cas9-gRNA complex. However, these procedures are quite toxic for the organoids. Here, we describe the use of the "nanoblade (NB)" technology, which outperformed by far gene-editing levels achieved to date for murine- and human tissue-derived organoids. We reached up to 75% of reporter gene knockout in organoids after treatment with NBs. Indeed, high-level NB-mediated knockout for the androgen receptor encoding gene and the cystic fibrosis transmembrane conductance regulator gene was achieved with single gRNA or dual gRNA containing NBs in murine prostate and colon organoids. Likewise, NBs achieved 20%-50% gene editing in human organoids. Most importantly, in contrast to other gene-editing methods, this was obtained without toxicity for the organoids. Only 4 weeks are required to obtain stable gene knockout in organoids and NBs simplify and allow rapid genome editing in organoids with little to no side effects including unwanted insertion/deletions in off-target sites thanks to transient Cas9/RNP expression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2023.06.004

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tiroille, V., Krug, A., Bokobza, E., Kahi, M., Bulcaen, M., Ensinck, M. M., Geurts, M. H., Hendriks, D., Vermeulen, F., Larbret, F., Gutierrez-Guerrero, A., Chen, Y., Van Zundert, I., Rocha, S., Rios, A. C., Medaer, L., Gijsbers, R., Mangeot, P. E., Clevers, H., Carlon, M. S., Bost, F., & Verhoeyen, E.
Affiliations
  • Inserm (FR)
  • KU Leuven (BE)
  • Royal Netherlands Academy of Arts and Sciences (NL)
  • Universitair Ziekenhuis Leuven (BE)
  • Memorial Sloan Kettering Cancer Center (US)
  • Oncode Institute (NL)
  • Lyon 1 Université (FR)
Corresponding author
  • Bost, Frédéric
  • Verhoeyen, Els
Venue
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Published
2023-09
Volume
33
Pages
57-74
ISSN
2162-2531 (ISSN-L)
OpenAlex
W4379877991
Cited by
25
References
52
Citations by year
2026: 7 · 2025: 10 · 2024: 8
FWCI
2.23
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • Lirias (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • Koning Boudewijnstichting (2020-J1810150-E015, S001221N)
  • Institut National Du Cancer
  • Roche
  • Conseil Régional Provence-Alpes-Côte d'Azur
  • Agence Nationale de la Recherche
  • French Government Ministry of Higher Education Research and Innovation
  • Fonds Wetenschappelijk Onderzoek (12Z5920N, 1S29917N, 1SE8122N)
  • Canceropôle Provence-Alpes-Côte d’Azur
  • KU Leuven
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9 genome editing, organoids, gene delivery, androgen receptor, cystic fibrosis transmembrane conductance regulator, prostate organoids, colon organoids, human organoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review